Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of EBITDA Margin data on file, last reported at 53.31% in Q1 2026.

• Quarterly EBITDA Margin rose 1833.0% year-over-year to 53.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 41.73% (up 2944.0% YoY) and the FY2025 annual result came in at 37.06%, up 3906.0% from the prior year.
• EBITDA Margin advanced to 53.31% in Q1 2026, from 43.1% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 53.31% in Q1 2026 to a low of 175.18% in Q1 2022.
• A 5-year average of 26.66% and a median of 17.03% in 2022 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin soared 535469 bps — and 2023, when it tumbled 1280 bps.
• Tracing AUPH's EBITDA Margin over 5 years: stood at 98.82% in 2022, then surged by 33 bps to 65.8% in 2023, then surged by 96 bps to 2.79% in 2024, then soared by 1646 bps to 43.1% in 2025, then gained by 24 bps to 53.31% in 2026.
• The last three EBITDA Margin figures came in at 53.31% (Q1 2026), 43.1% (Q4 2025), and 40.49% (Q3 2025), per Business Quant data.